Download PDF
Dtsch Med Wochenschr 2015; 140(14): 1083-1092
DOI: 10.1055/s-0041-102647
Fachwissen
CME
© Georg Thieme Verlag KG Stuttgart · New York

Diagnostik und Therapie des hepatorenalen Syndroms

Diagnosis and therapy of the hepatorenal syndrome
Sandra Blomeyer   *   #
1   Klinik für Gastroenterologie und Hepatologie, Universitätsklinikum Essen, Universität Duisburg-Essen
,
Bartosz Tyczynski   *
2   Klinik für Nephrologie, Universitätsklinikum Essen
,
Guido Gerken   *
1   Klinik für Gastroenterologie und Hepatologie, Universitätsklinikum Essen, Universität Duisburg-Essen
,
Ali Canbay   *   #
1   Klinik für Gastroenterologie und Hepatologie, Universitätsklinikum Essen, Universität Duisburg-Essen
› Author Affiliations
Further Information

Publication History

Publication Date:
16 July 2015 (online)

Also available at
   Permissions and Reprints

Zusammenfassung

In Folge einer fortgeschrittenen Leberzirrhose kommt es zu einer portalen Hypertension, die für den überwiegenden Teil letaler Komplikationen bei Leberzirrhose verantwortlich ist. Die kompensatorische, splanchnische Vasodilatation führt langfristig zu einer Gegenregulation unter anderem über das Renin-Angiotensin-Aldosteron-System und dadurch zu einer Erhöhung des renalen Gefäßwiderstands. Hierdurch kann ein hepatorenales Syndrom (HRS) entstehen. Das HRS stellt sich als Nierenfunktionseinschränkung mit erhöhten Kreatinin-Werten dar. Das HRS wird über eine komplexe Ausschlussdiagnostik erkannt und rasch mittels Albumin und Vasokonstriktoren therapiert. Für eine Heilung ist die Verbesserung der Leberfunktion essenziell, was in vielen Fällen die Notwendigkeit einer Lebertransplantation bedeutet. Zur Überbrückung bis zur Transplantation kann die Anlage eines TIPS sinnvoll sein, sofern keine hepatische Enzephalopathie vorliegt. Da eine spontane bakterielle Peritonitis (SBP) ein erhebliches Risiko für die HRS-Entstehung ist, ist bei Patienten mit Leberzirrhose und SBP neben der Antibiotikagabe eine Prävention mittels Albumin ratsam.

Abstract

Portal hypertension occurs frequently in advanced liver cirrhosis and accounts for the majority of lethal complications. Compensatory splanchnic vasodilation and counter regulatory mechanisms (e. g. activation of the renin-angiotensin-aldosterone system) increase renal vascular resistance, which may facilitate acute kidney injury and the development of hepatorenal syndrome (HRS). HRS represents a functional, yet reversible renal impairment with elevated serum creatinine levels. Establishing the diagnosis, fluid challenge test and several investigations are needed to exclude acute kidney injury and other causes of renal failure. Early treatment with albumin and vasoconstrictors improves the prognosis of HRS patients. The only curative treatment of HRS so far is improvement of liver function implying liver transplantation in many cases. TIPS placement may be useful as a bridging tool to transplantation unless hepatic encephalopathy is present. Spontaneous bacterial peritonitis (SBP) is a relevant, independent risk factor for HRS. In patients with liver cirrhosis and SBP in addition to antibiotics, preventive albumin treatment is recommended.

Schlüsselwörter

Nierenversagen - Leberzirrhose - akutes Leberversagen - Intensivmedizin

Keywords

kidney failure - liver cirrhosis - acute liver failure - intensive care

* Autoren des Hauptteils


# Autoren des konkreten Falls


 

  • Literatur

  • 1 Gerbes AL, Sauerbruch T, Dathe K. Method report: German S3-guideline „ascites, spontaneous bacterial peritonitis, hepatorenal syndrome“. Z Gastroenterol 2011; 49: 780-787
    PubMedGoogle Scholar
  • 2 Wadei HM, Mai ML, Ahsan N, Gonwa TA. Hepatorenal syndrome: pathophysiology and management. Clin J Am Soc Nephrol 2006; 1: 1066-1079
    CrossrefPubMedGoogle Scholar
  • 3 Iwakiri Y. The molecules: mechanisms of arterial vasodilatation observed in the splanchnic and systemic circulation in portal hypertension. J Clin Gastroenterol 2007; 41: S288-294
    PubMedGoogle Scholar
  • 4 Karagiannakis DS, Papatheodoridis G, Vlachogiannakos J. Recent Advances in Cirrhotic Cardiomyopathy. Dig Dis Sci 2015; 60: 1141-1151
    CrossrefPubMedGoogle Scholar
  • 5 Ruiz-del-Arbol L, Monescillo A, Arocena C et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005; 42: 439-447
    CrossrefPubMedGoogle Scholar
  • 6 Chandok N, Watt KD. Pain management in the cirrhotic patient: the clinical challenge. Mayo Clin Proc 2010; 85: 451-458
    PubMedGoogle Scholar
  • 7 Ginès A, Escorsell A, Ginès P et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105: 229-236
    CrossrefPubMedGoogle Scholar
  • 8 Akriviadis E, Botla R, Briggs W et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 1637-1648
    CrossrefPubMedGoogle Scholar
  • 9 Martín-Llahí M, Guevara M, Torre A et al. Prognostic importance of the cause of renal failure in patients with cirrhosis. Gastroenterology 2011; 140: 488-496
    CrossrefPubMedGoogle Scholar
  • 10 Arroyo V, Ginès P, Gerbes AL et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23: 164-176
    CrossrefPubMedGoogle Scholar
  • 11 Gines P, Schrier RW. Renal failure in cirrhosis. N Engl J Med 2009; 361: 1279-1290
    CrossrefPubMedGoogle Scholar
  • 12 Salerno F, Gerbes A, Ginès P et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56: 1310-1318
    CrossrefPubMedGoogle Scholar
  • 13 Salerno F, Cazzaniga M, Merli M et al. Diagnosis, treatment and survival of patients with hepatorenal syndrome: a survey on daily medical practice. J Hepatol 2011; 55: 1241-1248
    CrossrefPubMedGoogle Scholar
  • 14 Verna EC, Brown RS, Farrand E et al. Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis. Dig Dis Sci 2012; 57: 2362-2370
    CrossrefPubMedGoogle Scholar
  • 15 Belcher JM, Sanyal AJ, Peixoto AJ et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology 2014; 60: 622-632
    CrossrefPubMedGoogle Scholar
  • 16 Mehta RL, Kellum JA, Shah SV et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11: R31
    CrossrefPubMedGoogle Scholar
  • 17 Piano S, Rosi S, Maresio G et al. Evaluation of the Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites. J Hepatol 2013; 59: 482-489
    CrossrefPubMedGoogle Scholar
  • 18 Rabie RN, Cazzaniga M, Salerno F, Wong F. The use of E / A ratio as a predictor of outcome in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt. Am J Gastroenterol 2009; 104: 2458-2466
    CrossrefPubMedGoogle Scholar
  • 19 Saner FH, Neumann T, Canbay A et al. High brain-natriuretic peptide level predicts cirrhotic cardiomyopathy in liver transplant patients. Transpl Int 2011; 24: 425-432
    CrossrefPubMedGoogle Scholar
  • 20 Saner F, Kavuk I, Lang H et al. Terlipressin and gelafundin: safe therapy of hepatorenal syndrome. Eur J Med Res 2004; 9: 78-82
    PubMedGoogle Scholar
  • 21 Arroyo V, García-Martinez R, Salvatella X. Human serum albumin, systemic inflammation, and cirrhosis. J Hepatol 2014; 61: 396-407
    CrossrefPubMedGoogle Scholar
  • 22 Jürgens G, Müller M, Garidel P et al. Investigation into the interaction of recombinant human serum albumin with Re-lipopolysaccharide and lipid A. J Endotoxin Res 2002; 8: 115-126
    PubMedGoogle Scholar
  • 23 Zarychanski R, Abou-Setta AM, Turgeon AF et al. Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. JAMA 2013; 309: 678-688
    CrossrefPubMedGoogle Scholar
  • 24 Sagi SV, Mittal S, Kasturi KS, Sood GK. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2010; 25: 880-885
    CrossrefPubMedGoogle Scholar
  • 25 Gerbes AL, Huber E, Gulberg V. Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to i.v. bolus administration. Gastroenterology 2009; 137: 1179; author reply 1179-1181
    PubMedGoogle Scholar
  • 26 Ghosh S, Choudhary NS, Sharma AK et al. Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study. Liver Int 2013; 33: 1187-1193
    CrossrefPubMedGoogle Scholar
  • 27 Hinz M, Wree A, Jochum C et al. High age and low sodium urine concentration are associated with poor survival in patients with hepatorenal syndrome. Ann Hepatol 2013; 12: 92-99
    PubMedGoogle Scholar
  • 28 Nazar A, Pereira GH, Guevara M et al. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2010; 51: 219-226
    CrossrefPubMedGoogle Scholar
  • 29 Dechêne A, El Fouly AH, Bechmann LP et al. Acute management of refractory variceal bleeding in liver cirrhosis by self-expanding metal stents. Digestion 2012; 85: 185-191
    CrossrefPubMedGoogle Scholar
  • 30 Barreto R, Fagundes C, Guevara M et al. Type-1 hepatorenal syndrome associated with infections in cirrhosis: natural history, outcome of kidney function, and survival. Hepatology 2014; 59: 1505-1513
    CrossrefPubMedGoogle Scholar
  • 31 Bai M, Qi XS, Yang ZP et al. TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis. World J Gastroenterol 2014; 20: 2704-2714
    CrossrefPubMedGoogle Scholar
  • 32 Yang Z, Han G, Wu Q et al. Patency and clinical outcomes of transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stents versus bare stents: a meta-analysis. J Gastroenterol Hepatol 2010; 25: 1718-1725
    CrossrefPubMedGoogle Scholar
  • 33 Bañares R, Nevens F, Larsen FS et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: The RELIEF trial. Hepatology 2013; 57: 1153-1162
    CrossrefPubMedGoogle Scholar
  • 34 Kribben A, Gerken G, Haag S et al. Effects of Fractionated Plasma Separation and Adsorption on Survival in Patients With Acute-on-Chronic Liver Failure. Gastroenterology 2012; 142: 782-789 e3
    CrossrefPubMedGoogle Scholar
  • 35 Singh V, Dhungana SP, Singh B et al. Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. J Hepatol 2012; 56: 348-354
    CrossrefPubMedGoogle Scholar
  • 36 Angeli P, Volpin R, Gerunda G et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999; 29: 1690-1697
    CrossrefPubMedGoogle Scholar
  • 37 Esrailian E, Pantangco ER, Kyulo NL et al. Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci 2007; 52: 742-748
    CrossrefPubMedGoogle Scholar
  • 38 Robertson M, Majumdar A, Garrett K et al. Continuous outpatient terlipressin infusion for hepatorenal syndrome as a bridge to successful liver transplantation. Hepatology 2014; 60: 2125-2126
    CrossrefPubMedGoogle Scholar
  • 39 Salerno F, Navickis RJ, Wilkes MM. Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta-analysis of randomized trials. Clin Gastroenterol Hepatol 2013; 11: 123-130 e1
    CrossrefPubMedGoogle Scholar
  • 40 Fernández J, Navasa M, Planas R et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133: 818-824
    CrossrefPubMedGoogle Scholar
  • 41 Whitfield K, Rambaldi A, Wetterslev J, Gluud C. Pentoxifylline for alcoholic hepatitis. Cochrane Database Syst Rev 2009; CD007339
    PubMedGoogle Scholar
  • 42 García-Compean D, Blanc P, Larrey D et al. Treatment of cirrhotic tense ascites with Dextran-40 versus albumin associated with large volume paracentesis: a randomized controlled trial. Ann Hepatol 2002; 1: 29-35
    PubMedGoogle Scholar